IRIS UniCatt

Papa, Alfredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.320
AS - Asia 5.306
EU - Europa 4.963
SA - Sud America 1.055
AF - Africa 146
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 3
Totale 17.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.143
SG - Singapore 2.440
DE - Germania 1.644
CN - Cina 1.353
BR - Brasile 849
SE - Svezia 764
IT - Italia 515
FR - Francia 488
VN - Vietnam 428
UA - Ucraina 398
GB - Regno Unito 279
IE - Irlanda 218
IN - India 198
FI - Finlandia 172
JP - Giappone 172
ID - Indonesia 171
RU - Federazione Russa 128
CA - Canada 100
TR - Turchia 90
AR - Argentina 82
HK - Hong Kong 70
PL - Polonia 69
ES - Italia 67
BD - Bangladesh 66
KR - Corea 50
IQ - Iraq 47
BE - Belgio 45
ZA - Sudafrica 45
MX - Messico 42
NL - Olanda 40
EC - Ecuador 39
IR - Iran 31
AT - Austria 30
PK - Pakistan 29
SA - Arabia Saudita 27
VE - Venezuela 25
CO - Colombia 19
MA - Marocco 18
LT - Lituania 16
JO - Giordania 15
AE - Emirati Arabi Uniti 13
CZ - Repubblica Ceca 13
EG - Egitto 13
RO - Romania 13
CI - Costa d'Avorio 12
IL - Israele 12
TN - Tunisia 12
UZ - Uzbekistan 12
CL - Cile 11
KE - Kenya 10
DZ - Algeria 9
JM - Giamaica 9
AZ - Azerbaigian 8
EU - Europa 8
HU - Ungheria 8
OM - Oman 8
PE - Perù 8
PH - Filippine 8
UY - Uruguay 8
CH - Svizzera 7
NP - Nepal 7
PY - Paraguay 7
BG - Bulgaria 6
CR - Costa Rica 6
ET - Etiopia 6
TW - Taiwan 6
GR - Grecia 5
BB - Barbados 4
CG - Congo 4
EE - Estonia 4
KZ - Kazakistan 4
LV - Lettonia 4
MY - Malesia 4
PT - Portogallo 4
RS - Serbia 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
BZ - Belize 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GA - Gabon 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
MM - Myanmar 3
MN - Mongolia 3
NI - Nicaragua 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
LY - Libia 2
Totale 17.767
Salva come PNG Salva come JPEG
Città #
Singapore 1.326
Chandler 921
Ashburn 646
San Jose 574
Jacksonville 257
Beijing 238
New York 226
Dublin 212
San Mateo 191
Hangzhou 173
Los Angeles 157
Hefei 154
Jakarta 150
Tokyo 150
Lauterbourg 147
Ho Chi Minh City 136
Ann Arbor 127
Boston 119
Nanjing 115
Dearborn 111
Wilmington 110
Munich 106
Hanoi 103
The Dalles 102
Milan 101
Frankfurt am Main 100
Nürnberg 92
Cattolica 82
Dallas 74
Moscow 72
Princeton 72
São Paulo 68
Hong Kong 65
Council Bluffs 56
Marseille 55
Houston 53
Helsinki 51
Rome 50
Izmir 49
Redwood City 48
Nanchang 46
Bremen 45
Brussels 43
Seoul 43
Lawrence 42
Redmond 41
Chicago 40
Santa Clara 40
Kent 38
Seattle 37
Woodbridge 37
Boardman 36
Buffalo 36
Warsaw 36
London 35
Montreal 31
Brooklyn 29
Paris 29
Shanghai 29
Fairfield 28
Changsha 27
Rio de Janeiro 27
Stockholm 27
Norwalk 26
Nuremberg 26
Kunming 25
Toronto 25
Turku 25
Kraków 24
Orem 24
San Francisco 24
Augusta 23
Baghdad 23
Hebei 23
Belo Horizonte 22
Denver 22
Lappeenranta 22
Phoenix 22
Pune 22
Shenyang 22
Trieste 22
Da Nang 21
Johannesburg 21
Andover 20
Lancaster 20
Mountain View 20
North Bergen 20
Atlanta 19
Chennai 19
Detroit 19
Guangzhou 19
Poplar 19
Tianjin 19
Jiaxing 18
Vienna 18
Düsseldorf 17
Kish 17
Amsterdam 16
Leawood 16
Manchester 16
Totale 9.237
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 367
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. 241
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 218
Early atherosclerosis in patients with inflammatory bowel disease. 212
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 209
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 208
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 204
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 197
Assessment of neurological manifestations in hospitalized patients with COVID-19 193
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 190
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 188
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 188
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 188
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 187
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 179
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 174
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 171
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 170
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 170
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 169
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 164
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 162
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 162
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 162
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 155
Use of infliximab in particular clinical settings: management based on current evidence. 154
Development and validation of predictive assessment of complicated diverticulitis score 154
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 151
-Extraintestinal manifestations in inflammatory Bowel disease. 150
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 148
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 147
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 146
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 145
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 145
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 139
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 139
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 138
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 138
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 137
A novel pathogenic role for microvasculature in inflammatory bowel disease. 136
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 135
Effect of moderate and heavy alcohol consumption on intestinal transit time 131
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 131
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 131
Biological therapies for inflammatory bowel disease: research drives clinics. 130
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 130
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 130
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 127
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 123
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 122
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 122
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 122
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 121
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 121
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 119
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 119
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 119
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 118
Can we predict the efficacy of anti-TNF-α agents? 117
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 117
A) Review article: inherited thrombophilia in inflammatory bowel disease. 115
Microbiota Composition in Diverticular Disease: Implications for Therapy 113
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 113
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 112
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 112
Radiomics could predict surgery at 10 years in Crohn's disease 111
Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case 111
Differentiation affects the release of exosomes from colon cancer cells and their ability to modulate the behavior of recipient cells 111
Mucosal healing in ulcerative colitis: surveillance or colectomy? 110
Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment 109
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 108
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 107
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 107
The Role of Microbiota in Pancreatic Cancer 106
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 106
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 106
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies 104
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 104
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 103
The dica endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists: An international study 102
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 102
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 102
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 102
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 101
Hot topics in surgical management of acute diverticulitiss 101
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 100
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 99
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 98
Microbiota Composition in Diverticular Disease: Implications for Therapy 97
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 97
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 97
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 96
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 96
Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa 95
New therapeutic approach in inflammatory bowel disease. 95
Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. 95
Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. 95
CT and MRI Evaluations in Crohn's Complications: A Guide for the Radiologist 94
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 94
Totale 13.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.498
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021215 0 0 0 0 0 0 0 0 0 20 176 19
2021/20221.060 63 78 21 111 47 21 12 214 38 68 168 219
2022/20232.307 299 297 157 418 135 301 88 188 263 45 74 42
2023/20241.230 57 319 53 70 42 174 68 43 45 77 135 147
2024/20252.679 60 88 249 68 238 81 111 124 329 286 570 475
2025/20266.710 1.104 241 442 866 1.205 316 1.236 359 551 390 0 0
Totale 18.019